PV-10 Chemoablation of Recurrent Breast Carcinoma

Provectus Biopharmaceuticals

Status and phase

Completed

Phase 1

Conditions

Breast Cancer

Treatments

Drug: PV-10 (rose bengal disodium 10%)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00237354

PV-10-BC-04

Details and patient eligibility

About

The objective of this study is to investigate the safety of intralesional (IL) PV-10 for the treatment of recurrent breast carcinoma. This study will also include a preliminary assessment of response of injected lesions by histologic assessment upon lesion excision at 1-3 weeks following IL PV-10 administration. Post-excision wound healing will be assessed clinically at 1 week and 4 weeks following excision of PV-10 injected lesions.

Full description

This is a single center, open label, ascending dose study. Subjects with at least one recurrent, histologically confirmed measurable soft tissue breast carcinoma who are candidates for lumpectomy (removal of the lesion from the site of recurrence in the breast or at another site) or mastectomy will receive a single intralesional injection of PV-10 into a single target lesion to uniformly infiltrate the target lesion and up to a 0.5 cm margin at a dose of up to 1.0 mL/cc lesion volume. Systemic and locoregional adverse events will be monitored over the study interval. Subject accrual and PV-10 administration will be stopped if more than 1 subject has a treatment related Grade 3 non-hematological or Grade 4 hematological toxicity within a period of two weeks after PV-10 administration.

Enrollment

15 estimated patients

Sex

Female

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Biopsy confirmed recurrent soft tissue breast carcinoma
At least one measurable target lesion at least 0.5 cm and no more than 3 cm in longest diameter
Performance Status: Karnofsky 70-100% or ECOG 0-2
Life Expectancy: At least 6 months
Hematopoietic:
- White blood cell count (WBC) at least 3000/mm3
- Absolute neutrophil count (ANC) at least 1.5 (1,500/mm3)
- Hemoglobin at least 10 g/dL
- Platelet count at least 100,000/mm3
Coagulopathy: International Normalized Ratio (INR) at least 1.5.
Renal Function: Creatinine = 0.05-0.11 mmol/L
Hepatic Function:
- Bilirubin = 3-21 umol/L
- AST/ALT ≤ 3 times the upper limit of normal (ULN)
Cardiovascular Function: No major cardiovascular disease
Thyroid Function: T3 (serum triiodothyronine), T4 (serum thyroxine) and THS (serum thyrotropin) within normal limits
Immunological Function: Adequate immune system function in the opinion of the investigator

Exclusion criteria

Radiation therapy to study lesions within 4 weeks
Chemotherapy or other systemic cancer therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin)
Local treatment (e.g., surgery, cryotherapy, radiofrequency ablation) to the treatment area within 4 weeks
Investigational agents within 4 weeks (or 5 half-lives)
Anti-tumor vaccine therapy within 12 weeks
Concurrent illness:
- Severe diabetes or extremity complications due to diabetes
- Significant concurrent disease or illness, psychiatric disorders, or alcohol or chemical dependence that would, in the opinion of the investigator, compromise subject safety or compliance or interfere with interpretation of study results
- Thyroid autoregulatory dysfunction, including thyroid disease (subclinical or ongoing), goiter, partial thyroidectomy, prior radioiodine- or surgically-treated Graves' hyperthyroidism, or cystic fibrosis
Pregnancy or fertile female subjects who are not using effective contraception, or who are lactating
Known or suspected brain metastases or spinal cord compression.